AI-Powered Rare Disease Diagnosis Market Report 2026

The artificial intelligence (AI)-powered rare disease diagnosis market size has grown exponentially in recent years. It will grow from $1.99 billion in 2025 to $2.56 billion in 2026 at a compound annual growth rate (CAGR) of 28.9%. The growth in the historic period can be attributed to increasing diagnostic challenges for rare conditions, expansion of genetic testing availability, rising investments in rare disease research, growing use of data analytics in healthcare, early adoption of ai-driven diagnostic tools.

The artificial intelligence (AI)-powered rare disease diagnosis market size is expected to see exponential growth in the next few years. It will grow to $7.08 billion in 2030 at a compound annual growth rate (CAGR) of 28.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising deployment of ai-assisted clinical decision support, expansion of genomic sequencing integration, growing investment in rare disease screening programs, increasing demand for diagnostic efficiency. Major trends in the forecast period include increasing use of ai for pattern recognition in rare diseases, rising adoption of genomic data analytics platforms, growing integration of multi-modal patient data, expansion of cloud-based diagnostic solutions, enhanced focus on early and accurate diagnosis.

The rising prevalence of autoimmune disorders is expected to drive the growth of the artificial intelligence (AI)-powered rare disease diagnosis market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body’s own healthy cells and tissues, leading to inflammation and tissue damage. The increasing number of individuals experiencing immune system dysfunctions is driving demand for early diagnosis, advanced treatments, and continuous monitoring to effectively manage symptoms. AI-powered rare disease diagnosis supports autoimmune disorder management by rapidly identifying complex conditions, guiding personalized treatment decisions, and improving overall diagnostic accuracy. For example, in January 2025, the Mayo Clinic reported that approximately 15 million people are estimated to have one or more of 105 autoimmune diseases. As a result, the growing prevalence of autoimmune disorders is fueling the expansion of the AI-powered rare disease diagnosis market.

Key companies in the AI-powered rare disease diagnosis market are focusing on innovative technologies, such as unified genomic diagnostics solutions, to improve diagnostic accuracy, reduce turnaround time, and provide comprehensive insights into complex genetic disorders. Unified genomic diagnostics integrates whole-genome sequencing with AI-driven analysis to deliver complete genetic insights. For instance, in October 2023, Oxford Nanopore Technologies plc, a UK-based biotechnology company, partnered with Fabric Genomics Inc., a US-based AI company, to launch an integrated whole-genome sequencing solution. This platform combines rapid nanopore sequencing with AI-powered variant interpretation to accelerate rare disease diagnosis, delivering actionable insights to clinicians and enhancing diagnostic speed and accuracy, particularly in pediatric care.

In September 2025, SeqOne, a France-based provider of AI-powered genomic analysis and clinical decision support tools, acquired Congenica for an undisclosed amount. Through this acquisition, SeqOne aims to integrate its AI-driven next-generation sequencing (NGS) platform with Congenica’s clinical interpretation expertise and decision support software. This enhances SeqOne’s capabilities in rare and inherited disease diagnostics, expands its global reach, and positions it as a leading software-focused company in clinical genomics. Congenica is a UK-based provider of genomic data analysis and interpretation solutions, offering clinical decision support and variant interpretation services for rare, inherited, and genetic diseases.

Major companies operating in the artificial intelligence (AI)-powered rare disease diagnosis market are Ambry Genetics Corporation, MedGenome Inc., Sophia Genetics SA, Variantyx Inc., Atropos Health Inc., Congenica Ltd., Saventic Care Sp. z o.o., Rapid Innovation LLC, Centogene N.V., Impilo AB, ThinkGenetic Inc., ClairLabs Ltd., 3billion Inc., OpenEvidence Inc., GenomeUp S.R.L., Mendel.ai Inc., RareSum GmbH, DeepRare AI Solutions, Zebra-Llama Project.

North America was the largest region in the artificial intelligence (AI)-powered rare disease diagnosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered rare disease diagnosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-powered rare disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI-powered rare disease diagnosis market by increasing costs of imported sequencing instruments, diagnostic sensors, advanced computing hardware, and specialized analytics software. Healthcare providers and research institutes in North America and Europe are most affected due to reliance on imported genomic and imaging technologies, while Asia-Pacific faces higher costs for technology exports. These tariffs are increasing overall system deployment costs and slowing adoption among smaller healthcare facilities. However, they are also encouraging domestic development of AI software, regional manufacturing of diagnostic equipment, and investment in localized genomic analysis capabilities.

The artificial intelligence (AI)-powered rare disease diagnosis market research report is one of a series of new reports that provides artificial intelligence (AI)-powered rare disease diagnosis market statistics, including artificial intelligence (AI)-powered rare disease diagnosis industry global market size, regional shares, competitors with a artificial intelligence (AI)-powered rare disease diagnosis market share, detailed artificial intelligence (AI)-powered rare disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-powered rare disease diagnosis industry. This artificial intelligence (AI)-powered rare disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-powered rare disease diagnosis refers to the use of advanced algorithms and machine learning techniques to accurately identify uncommon medical conditions. These systems analyze complex patient data, including genetic, clinical, and imaging information, to detect patterns that traditional diagnostic methods may overlook.

The primary components of AI-powered rare disease diagnosis include software, hardware, and services. The software consists of programs, data, and instructions that guide a computer or device in performing specific diagnostic tasks. Key technologies include machine learning, deep learning, natural language processing, computer vision, and others. Deployment can be through cloud-based or on-premises solutions. Applications cover diagnosis of genetic disorders, autoimmune disorders, metabolic disorders, infectious diseases, and more, serving end-users such as hospitals, diagnostic centers, research institutes, specialty clinics, and other healthcare organizations.

The artificial intelligence (AI)-powered rare disease diagnosis market includes revenues earned by entities by providing services such as genomic sequencing analysis, clinical data integration, artificial intelligence (AI)-based imaging interpretation, predictive analytics for rare diseases, and personalized treatment recommendations. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-powered rare disease diagnosis market also includes sales of genetic testing kits, imaging scanners, biosensors, lab automation instruments, point-of-care testing devices, wearable health monitors, sequencing machines, microfluidic chips, and pathology slide scanners. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.